Compare BW & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | EVMN |
|---|---|---|
| Founded | 1867 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.7M | 628.9M |
| IPO Year | N/A | 2025 |
| Metric | BW | EVMN |
|---|---|---|
| Price | $8.36 | $19.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.50 | ★ $38.60 |
| AVG Volume (30 Days) | ★ 3.1M | 329.7K |
| Earning Date | 11-04-2025 | 02-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $721,285,000.00 | $13,000,000.00 |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | $4.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 80.30 | ★ 160.00 |
| 52 Week Low | $0.22 | $13.89 |
| 52 Week High | $8.58 | $24.03 |
| Indicator | BW | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 70.44 | N/A |
| Support Level | $7.80 | N/A |
| Resistance Level | $8.58 | N/A |
| Average True Range (ATR) | 0.65 | 0.00 |
| MACD | 0.25 | 0.00 |
| Stochastic Oscillator | 93.64 | 0.00 |
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.